Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients.

Mol Oncol · 2025 · PMC12234382 · PMID 38956984

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While the SCLC‐A and SCLC‐N subtypes showed a trend toward improvement in median OS with the addition of atezolizumab, there was no difference in the SCLC‐P subtype. 3.5.1 Molecular subtypes and CTCs Molecular subtyping CTCs into the four SCLC subtypes is feasible [ 100 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.